Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

The arrival of cell-based therapies is a revolution in medicine. However, its safe clinical
application in a rational manner depends on reliable, clinically applicable methods for …

Cancer immunotherapy uses the immune system and its components to mount an anti-tumor
response. During the last decade, it has evolved from a promising therapy option to a robust …

Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …

Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in
cancer treatment following the impressive results in hematologic malignancies …

Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently
surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired …

Chimeric antigen receptor (CAR)-T cells have emerged as a promising treatment modality
for various hematologic and solid malignancies over the past decade. Animal models …

Introduction Malignant pleural mesothelioma (MPM) is an incurable malignant disease,
which results from chronic exposition to asbestos in at least 70% of the cases. Fibroblast …

Recent clinical success has underscored the potential for immunotherapy based on the
adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and …